This study was designed to evaluate the safety, pharmacokinetics, and clinical activity of pazopanib combined with paclitaxel to determine the recommended phase II dose in the first-line setting in patients with advanced solid tumors. Patients were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated regimen (MTR) of once daily pazopanib plus paclitaxel administered every 3 weeks at four dose levels (DL1-4). Safety, pharmacokinetics, pharmacogenetics, and disease assessments were performed. Twenty-eight patients received treatment. One patient at DL1 had dose-limiting toxicity (DLT) of elevated hepatic enzymes.
Introduction
Angiogenesis remains an important pathway in tumor initiation, growth, and response to therapy. Vascular endothelial growth factor (VEGF) is a potent endothelial-specific angiogenic factor that is an important regulator of the angiogenic process (1, 2) , and elevated VEGF receptor (VEGFR) levels have been found to confer a poor prognosis in many solid tumors, including non-small cell lung cancer (NSCLC) and melanoma (3, 4) .
Randomized controlled trials have demonstrated the clinical benefit of inhibition of the VEGF pathway by small molecule multi-targeted tyrosine kinase inhibitors (TKIs), and a number of these agents including sunitinib, sorafenib, pazopanib, axitinib, and vandetanib are approved as monotherapy for a variety of advanced solid tumors (5−11) . However, despite demonstration of single-agent activity, combination with standard chemotherapy regimens for these agents in other tumor types has been challenging. In some cases, combinations have not been tolerable (12, 13) , while in other cases the combination was tolerable, but failed to deliver efficacy. For example, sorafenib had been reported to have promising activity in early phase studies for NSCLC (14, 15 ). Yet when sorafenib was added to paclitaxel and carboplatin in the first-line setting for NSCLC the primary endpoint of improved overall survival (OS) or even progression free survival (PFS) was not met. Furthermore, in the subgroup of patients with squamous cell histology, the sorafenib combination was associated with increased mortality (16) .
In contrast, bevacizumab, a monoclonal antibody to VEGF-A, when combined with paclitaxel and carboplatin, demonstrated a statistically significant survival advantage (median OS, 12.3 months versus 10.3 months) over chemotherapy alone (17) in patients with non-squamous NSCLC, while patients with squamous cell NSCLC did not tolerate this combination (18) . Pazopanib (Votrient) is an orally bioavailable, small molecule, competitive TKI of VEGFR (-1, -2, and -3), platelet-derived growth factor receptor (PDGFR) α-, β-, and c-Kit (19) , which is approved as monotherapy at a dose of 800 mg daily for the treatment of patients with advanced renal cell carcinoma (RCC) (8) and advanced soft-tissue sarcoma (STS) who have received prior chemotherapy (9). Short-term treatment with pazopanib 800 mg demonstrated single-agent activity in patients with early-stage NSCLC in the pre-operative setting in a proof of concept study that supported further exploration of pazopanib in NSCLC (20) .
Since paclitaxel is a backbone of standard chemotherapeutic regimens used in a number of malignancies, including NSCLC, we had an interest in exploring the combination of pazopanib and paclitaxel in solid tumors. Additionally, preclinical evidence suggested the possibility of synergy from the combination of anti-angiogenic agents with taxanes (21) , and recent data suggested synergism between paclitaxel and pazopanib via inhibition of aurora A in anaplastic thyroid cancer (22) . Previous studies demonstrated that pazopanib could not be readily combined with paclitaxel 175 mg/m 2 and carboplatin area under the plasma drug concentration curve (AUC) 5 administered every 3 weeks at doses higher than pazopanib 200 mg (23, 24) . However, it was feasible to administer pazopanib 800 mg with a weekly regimen of paclitaxel 80 mg/m 2 , which resulted in a 26% higher geometric mean paclitaxel AUC that was similar to the systemic exposure of a paclitaxel dose of 100 mg/m 2 (25) .
The current study was designed to evaluate the safety of pazopanib in combination with paclitaxel administered every 3 weeks and to determine the recommended phase II dose for this combination in the first-line setting in patients with advanced solid tumors. Due to the expected increase in exposure of paclitaxel when administered in combination with pazopanib, careful dose escalation and real-time pharmacokinetic analyses were performed. This study (Clinicaltrials.gov NCT00866528) was conducted in accordance with the
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Patients and Methods
Declaration of Helsinki and the International Conference on Harmonization Good Clinical
Practice guidelines, and was approved by institutional review boards. All patients provided written informed consent before any study procedures were performed.
Study Design and Treatment
This was an open-label, multicenter, phase I study of pazopanib in combination with paclitaxel. Pazopanib (Votrient™, GlaxoSmithKline, North Carolina, USA) was administered orally once daily starting on day 2 of cycle 1 in combination with paclitaxel (TAXOL® 
Endpoints and Safety and Response Assessments
The primary outcome measure was safety and tolerability of pazopanib in combination with paclitaxel based on the frequency and nature of DLTs, adverse events (graded according to NCI CTCAE version 3.0), vital signs, electrocardiograms, and clinical laboratory parameters.
Safety assessments were performed every week until completion of cycle 2, on days 1 and 8 of subsequent cycles, and then every 4 weeks during pazopanib monotherapy treatment.
Disease assessments were performed approximately every 6 weeks for the first 18 weeks and every 8 weeks thereafter until disease progression. Tumor response was assessed according to RECIST, version 1.0 (26).
Pharmacokinetic Assessments
To determine the effect of pazopanib on the pharmacokinetics of paclitaxel, blood samples (2 mL) were collected for the analysis of plasma paclitaxel concentrations on day 1, cycle 1 (paclitaxel alone) and on day 1, cycle 2 (paclitaxel plus pazopanib) pre-dose, and at the following times after the start of the paclitaxel infusion: 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8 to 10, and 24 hours. To estimate the pharmacokinetics of pazopanib in the presence of paclitaxel, additional blood samples (2 mL) were collected on day 1, cycle 2 pre-dose, and 1, 2, 4, 8, and 24
hours after the start of the paclitaxel infusion. Plasma samples were analyzed for pazopanib using a validated analytical method based on protein precipitation followed by high-performance 9 liquid chromatography tandem mass spectrometry (HPLC/MS/MS) analysis. Plasma samples were analyzed for paclitaxel by Advion Bioanalytical Labs (Ithaca, New York, USA) using a validated analytical method based on solid-phase extraction followed by HPLC/MS/MS analysis.
To investigate observed hepatotoxicity in one patient, 3 plasma samples obtained during the course of the event were analyzed for pazopanib and were also analyzed for simvastatin and simvastatin acid using a validated analytical method based on solid-phase extraction followed by HPLC/MS/MS analysis.
Pharmacogenetic Assessments
The evaluation of the association of genetic variations in host DNA with safety, tolerability, and pharmacokinetics was an exploratory objective in this study. Each patient had a 10-mL blood sample taken for analysis. DNA extraction was performed by Covance (United Kingdom). The 
Statistical Analysis
Analyses were based on all patients who received at least one dose of pazopanib and one dose of paclitaxel within at least one cycle of treatment. Pharmacokinetic parameters were calculated by standard noncompartmental methods using WinNonlin Professional Edition version 5.2 (Pharsight Corporation, California, USA). The objective response rate (ORR),
Results
Patient characteristics
Thirty patients were enrolled from 4 study sites from July 2009 to May 2011. Two patients did not receive pazopanib and were not included in the analyses. All patients had a diagnosis of either NSCLC or melanoma. Table 1 summarizes patient characteristics.
Dose escalation and toxicity
Four dose levels were explored and are shown in Table 2 The first DLT, asymptomatic grade 4 elevated hepatic enzymes, with grade 2 bilirubin elevation, occurred in cohort 1 after the administration of one dose of paclitaxel (135 mg/m 2 ) and 21 days of pazopanib, which the patient took as 400 mg twice daily (in error) instead of 800 mg once daily. Pazopanib treatment was permanently discontinued; however, hepatic enzymes remained high until a concurrent medication, simvastatin (80 mg daily), was also discontinued (see Supplementary Table S1 ). Three blood samples drawn during the course of this event revealed plasma pazopanib concentrations within the expected range. However, plasma concentrations of simvastatin and simvastatin acid approximately 7 h after the last dose of pazopanib and 16.5 h after the last dose of simvastatin were 14.7 ng/mL (approximately 4-fold greater than expected) and 20.1 ng/mL (approximately 10-fold greater than expected), respectively (27) , indicating that a drug-drug interaction between pazopanib and simvastatin was present in this patient (see Supplementary Table S2 lower dose (600 mg daily). Of note, there were no DLTs of neutropenia in this study; however, the lowest median neutrophil count in cycle 1 was observed in cohort 2 ( Table 2 ).
In cohort 3 (PAC 150/PAZ 800), two patients had grade 3 ALT elevations during the second cycle of treatment that did not meet DLT criteria. In both patients, plasma pazopanib concentrations were within the expected range of concentrations for an 800 mg dose of pazopanib; viral serology and ANA tests were negative. In one patient, treatment with pazopanib was interrupted and later re-started for cycle 3 of treatment at a reduced dose (400 mg); after re-challenge there was a mild and transient grade 2 ALT elevation. There was no elevation of bilirubin. No pharmacogenetic testing was performed. In the second patient, pazopanib treatment was discontinued. Pharmacogenetic analysis of a blood sample revealed wild-type genotypes for UGT1A1, HFE, ABCB1, CYP3A4, CYP2C8, and SLCO1B1; however, the patient was homozygous for the ABCG2 *2/*2 genotype, associated with functional impairment of the transporter.
All 28 patients who received at least one dose of both study drugs reported at least one adverse event regardless of causality during the study. Overall, the most frequently reported treatment-emergent adverse events (any grade occurring in ≥30% of patients) were alopecia (86%), fatigue (82%), hypertension (71%), nausea (68%), diarrhea (61%), vomiting (54%), dysgeusia (50%), myalgia (50%), rash (50%),neutropenia (46%), arthralgia (43%), decreased appetite (43%), , hair color changes (43%), headache (43%), peripheral neuropathy (43%), pain in extremity (39%), constipation (32%), dizziness (32%), and hepatic enzyme increased (32%); most were grade 1 or 2 in severity (Table 3) . At the MTR (PAC 150/PAZ 800), the incidences were fatigue (92%), alopecia (83%), nausea (75%), rash (75%), hypertension (67%), diarrhea (67%), dysgeusia (58%), myalgia (50%), vomiting (50%), neutropenia (42%), headache (42%), peripheral neuropathy (33%), arthralgia (33%), decreased appetite (33%), and hair-color changes (33%) . Overall, the most frequently reported treatment-emergent grade 3 and 4 adverse events were neutropenia (6 and 3 patients, respectively) and hepatic enzyme elevations (4 and 1 patient, respectively). There were no embolic or thrombotic events and no severe (grade 3 or above)
hemorrhagic events reported in the study. Permanent discontinuation of study treatment due to adverse events occurred in 5 patients; three patients due to elevations in liver enzymes, one patient due to subcutaneous (paravertebral) abscess, and one patient due to tachycardia (for this patient paclitaxel was discontinued but not pazopanib).
Treatment exposure
The median number of cycles of paclitaxel administered was 5 to 6 cycles across all cohorts and the median dose of paclitaxel and pazopanib administered was the planned dose for each cohort, with the exception of cohort 2 where the median pazopanib dose was lower (737 mg) than the intended dose (800 mg) (see Supplementary Table S3 ). The median duration of pazopanib treatment was 3.8, 5.3, 6.9, and 5.0 months for cohorts 1, 2, 3, and 4, respectively. One patient with ocular melanoma continued to receive treatment with 800 mg pazopanib monotherapy for 24 months after completion of his 6 cycles of paclitaxel plus pazopanib; his overall treatment duration was 28 months (Figure 1 ).
Pharmacokinetics
Co-administration of pazopanib and paclitaxel resulted in an increase in systemic exposure to paclitaxel relative to administration of paclitaxel alone by approximately 38% at the 800 mg once daily on the systemic disposition of paclitaxel (see Supplementary Table S4 ).
There were no consistent changes in systemic exposure to pazopanib as measured by maximum concentration (Cmax), AUC from time of dose to 24 hours (AUC(0-24)), or concentration at 24 hours following administration (C24) across the paclitaxel dose levels explored. These results indicate that there was no concentration-dependent affect of paclitaxel on the systemic exposure of pazopanib.
Clinical activity
Clinical activity was observed in all four cohorts, with 10 of 28 evaluable patients achieving a PR for an ORR of 36% for the total population ( Figure 3 and Supplementary Table   S5 ), and stable disease of ≥12 weeks in 10 additional patients. In the subset of patients with NSCLC, the ORR was 45%, (PR in 5 of 11 patients) and stable disease of ≥12 weeks was observed in 3 of 11 patients. In the subset of patients with melanoma, the ORR was 29%, (PR in The most common treatment-related toxicities observed for the combination of pazopanib and paclitaxel in the current study were expected based on the known safety profile of each individual agent and included alopecia, fatigue, hypertension, nausea, diarrhea, dysgeusia, vomiting, and neutropenia. Although events were mostly grade 1 or 2 in severity, the incidence of some events including fatigue, nausea, hypertension, dysgeusia, and rash was somewhat higher than expected. In the current study, a large proportion of patients (67%) entered with baseline hypertension; it is unclear whether this influenced the incidence of hypertension reported. Previous studies of the combination of pazopanib with weekly paclitaxel have also reported high incidences of fatigue and nausea (25, 32) ; therefore it is possible that these events could represent potential synergistic toxicities for the combination of pazopanib and paclitaxel.
Of note, hematologic toxicity was not dose-limiting in the current study; this contrasts with the experience with the combination of pazopanib with paclitaxel 175 mg/m 2 and carboplatin AUC 5, where myelosuppression was the DLT for the combination (23, 24) . DLTs reported in the current study included rash and hepatotoxicity.
Hepatotoxicity is an expected event for pazopanib, manifested by increases in serum transaminases (ALT, AST) and bilirubin, with the majority (92.5%) of transaminase elevations occurring within the first 18 weeks of treatment (33) . In clinical trials in RCC and STS, approximately 18% of patients experienced elevations of ALT greater than 3x the upper limit of normal (ULN), 5% experienced elevations of ALT greater than 8xULN, and 2% had concurrent This anecdotal observation of hepatotoxicity in conjunction with concurrent simvastatin treatment resulted in the conduct of a meta-analysis to evaluate the effects of concomitant pazopanib and statin use on the incidence of elevated ALT using data from 11 pazopanib clinical studies (37) . The meta-analysis showed the incidence of ALT elevation (≥3×ULN) was 27% in patients receiving both pazopanib and simvastatin, which was significantly higher than the shown to play a role in metastatic melanoma (43) , studies to explore the combination of carboplatin, paclitaxel, and anti-angiogenic agents such as sorafenib and bevacizumab have been performed; however, these studies have not shown improved efficacy compared with the carboplatin and paclitaxel doublet (30, 42) . In the current study, the response rate for melanoma was 29% (5 of 17 patients with PR) with an additional 41% (7 of 17 patients) demonstrating SD of >12 weeks and one patient diagnosed with ocular melanoma maintained antitumor response for more than 100 weeks. Additionally, an ongoing phase II study of pazopanib in combination with a weekly regimen of paclitaxel for the first-line treatment of unresectable melanoma has reported data from a planned interim analysis in 20 patients and demonstrated a response rate of 42% (32) ; this study will continue to accrue 60 patients with a primary endpoint of 6-month PFS.
These studies suggest that the combination of pazopanib and paclitaxel is active in melanoma and warrants further investigation.
In the current study, the response rate for NSCLC was 45% (5 of 11 patients with PR)
with an additional 27% (3 of 11 patients) demonstrating SD of >12 weeks. The clinical activity 21 observed in patients with NSCLC in the current study suggests further investigation of the combination of pazopanib and paclitaxel is warranted. Recent data reported with docetaxel and nintedanib in the second-line setting for advanced NSCLC demonstrated a significant improvement of both PFS and OS for the combination treatment compared with single-agent docetaxel (44) . In this setting, combination treatment with docetaxel and nintedanib continued until disease progression; this approach may be worth considering in future studies of the combination of pazopanib and paclitaxel. In our phase 1 trial, 50% of patients completed the 6 cycles of combination therapy and were continued on single-agent pazopanib for a range of 2 to 24 months.
Since the current study was initiated, treatment paradigms in both melanoma and NSCLC have undergone a rapid transformation. In melanoma, the emergence of newer targeted agents including vemurafenib, dabrafenib, and trametinib have resulted in higher response rates and improved clinical outcomes, especially for patients with V600 mutation positive tumors (45) .
The current study did not prospectively test for the status of V600 mutations in the melanoma subset of patients. With the availability of an approved test for this marker, future studies should incorporate evaluation of this marker. Additionally, emerging data from studies in both melanoma and NSCLC with immune therapies including ipilimumab, the PD-1 checkpoint inhibitors, and combinations of these agents, suggest that the landscape of treatment in the firstline metastatic setting for each of these tumor types will continue to change (45, 46) . In the face of these changes, future studies of the combination of pazopanib and paclitaxel will need to carefully evaluate the appropriate setting for use of this combination.
In summary, the current study identified pazopanib 800 mg daily and paclitaxel 150 mg/m 2 administered every 3 weeks as the recommended phase II dose for patients with 22 advanced solid tumors. The toxicity profile was consistent with the safety profile of each individual agent and was manageable; although the incidence of some toxicities may be higher than expected from single-agent treatment. In the presence of pazopanib, exposure to paclitaxel increased by 38%; however, there was no dose-or concentration-dependent effect of pazopanib 400 mg or 800 mg once daily on the systemic disposition of paclitaxel. Clinical activity of this combination in both melanoma and NSCLC suggests further evaluation of this combination is warranted.
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